Unichem Laboratories' (NSE:UNICHEMLAB) Promising Earnings May Rest On Soft Foundations

Despite posting some strong earnings, the market for Unichem Laboratories Limited's (NSE:UNICHEMLAB) stock hasn't moved much. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.

earnings-and-revenue-history
NSEI:UNICHEMLAB Earnings and Revenue History July 12th 2025
Advertisement

How Do Unusual Items Influence Profit?

For anyone who wants to understand Unichem Laboratories' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from ₹102m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Unichem Laboratories doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Unichem Laboratories.

Our Take On Unichem Laboratories' Profit Performance

Arguably, Unichem Laboratories' statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Unichem Laboratories' statutory profits are better than its underlying earnings power. The good news is that it earned a profit in the last twelve months, despite its previous loss. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Unichem Laboratories' balance sheet by clicking here.

Today we've zoomed in on a single data point to better understand the nature of Unichem Laboratories' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:UNICHEMLAB

Unichem Laboratories

A pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally.

Adequate balance sheet and slightly overvalued.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5363.1% undervalued
130 users have followed this narrative
0 users have commented on this narrative
18 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18051.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.323.4% undervalued
4 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2451.6% undervalued
21 users have followed this narrative
1 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

KA
kapirey
300750 logo
kapirey on Contemporary Amperex Technology ·

High-quality compounder with structural growth tailwinds

Fair Value:CN¥735.1341.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
6831 logo
kapirey on Green Tea Group ·

Scalable store expansion model

Fair Value:HK$17.3651.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
PLT logo
kapirey on Pilatus Marine ·

Thailand-based provider of LPG (liquefied petroleum gas) and petrochemical transportation services

Fair Value:฿0.6314.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.6% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.228.1% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9326.6% undervalued
1399 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative